Millennium Pharmaceuticals, Inc. (MLNM) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Millennium Pharmaceuticals, Inc. (MLNM)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

From: Icebrg	11/12/2007 11:30:19 AM
	Read Replies (1) of 3044

Millennium Pharmaceuticals "outperform" Monday, November 12, 2007 5:16:46 AM ET Robert W. Baird NEW YORK, November 12 (newratings.com) - Analyst Christopher J Raymond of Robert W Baird reiterates his "outperform" rating on Millennium Pharmaceuticals Inc (MLNM.NAS). The target price is set to $15. In a research note published this morning, the analyst mentions that ASH abstracts indicate positive Velcade data-points in front-line multiple myeloma. There is increased confidence in ASH 2007 acting as a turning point for Velcade, improving its commercial prospects for several years, the analyst says.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next